Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

326 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
End-point definition and trial design to advance tuberculosis vaccine development.
Garcia-Basteiro AL, White RG, Tait D, Schmidt AC, Rangaka MX, Quaife M, Nemes E, Mogg R, Hill PC, Harris RC, Hanekom WA, Frick M, Fiore-Gartland A, Evans T, Dagnew AF, Churchyard G, Cobelens F, Behr MA, Hatherill M. Garcia-Basteiro AL, et al. Among authors: churchyard g. Eur Respir Rev. 2022 Jun 7;31(164):220044. doi: 10.1183/16000617.0044-2022. Print 2022 Jun 30. Eur Respir Rev. 2022. PMID: 35675923 Free PMC article. Review.
Key issues in the clinical development and implementation of TB vaccines in South Africa.
Rustomjee R, Mcleod R, Hanekom W, Steel G, Mahomed H, Hawkridge A, Welte A, Sinanovic E, Loots G, Grobler A, Mvusi L, Gray G, Hesseling A, Ginsberg A, Lienhardt C, Shea J, Tong X, Lockhart S, Churchyard GJ. Rustomjee R, et al. Among authors: churchyard gj. Tuberculosis (Edinb). 2012 Sep;92(5):359-64. doi: 10.1016/j.tube.2012.05.001. Epub 2012 Jun 12. Tuberculosis (Edinb). 2012. PMID: 22698868
Designing an adaptive phase II/III trial to evaluate efficacy, safety and immune correlates of new TB vaccines in young adults and adolescents.
Rustomjee R, McClain B, Brennan MJ, McLeod R, Chetty-Makkan CM, McShane H, Hanekom W, Steel G, Mahomed H, Ginsberg AM, Shea J, Lockhart S, Self S, Churchyard GJ. Rustomjee R, et al. Among authors: churchyard gj. Tuberculosis (Edinb). 2013 Mar;93(2):136-42. doi: 10.1016/j.tube.2012.11.005. Epub 2012 Dec 23. Tuberculosis (Edinb). 2013. PMID: 23266259
High-dose rifapentine with moxifloxacin for pulmonary tuberculosis.
Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA; RIFAQUIN Trial Team. Jindani A, et al. N Engl J Med. 2014 Oct 23;371(17):1599-608. doi: 10.1056/NEJMoa1314210. N Engl J Med. 2014. PMID: 25337749 Free PMC article. Clinical Trial.
Tuberculosis vaccines and prevention of infection.
Hawn TR, Day TA, Scriba TJ, Hatherill M, Hanekom WA, Evans TG, Churchyard GJ, Kublin JG, Bekker LG, Self SG. Hawn TR, et al. Among authors: churchyard gj. Microbiol Mol Biol Rev. 2014 Dec;78(4):650-71. doi: 10.1128/MMBR.00021-14. Microbiol Mol Biol Rev. 2014. PMID: 25428938 Free PMC article. Review.
Safety and immunogenicity of H1/IC31®, an adjuvanted TB subunit vaccine, in HIV-infected adults with CD4+ lymphocyte counts greater than 350 cells/mm3: a phase II, multi-centre, double-blind, randomized, placebo-controlled trial.
Reither K, Katsoulis L, Beattie T, Gardiner N, Lenz N, Said K, Mfinanga E, Pohl C, Fielding KL, Jeffery H, Kagina BM, Hughes EJ, Scriba TJ, Hanekom WA, Hoff ST, Bang P, Kromann I, Daubenberger C, Andersen P, Churchyard GJ. Reither K, et al. PLoS One. 2014 Dec 9;9(12):e114602. doi: 10.1371/journal.pone.0114602. eCollection 2014. PLoS One. 2014. PMID: 25490675 Free PMC article. Clinical Trial.
Regarding the effect of cured tuberculosis disease on longevity.
Lalli M, Houben R, Churchyard G, White RG. Lalli M, et al. Among authors: churchyard g. Int J Tuberc Lung Dis. 2015 Mar;19(3):367. doi: 10.5588/ijtld.14.0852. Int J Tuberc Lung Dis. 2015. PMID: 25692935 No abstract available.
326 results